Zentalis Pharmaceuticals (ZNTL) Long-Term Deferred Tax (2019 - 2021)
Zentalis Pharmaceuticals' (ZNTL) quarterly Long-Term Deferred Tax came in at $716000.0 in Q2 2021, down 79.69% quarter-over-quarter from $3.5 million in Q1 2020.
Zentalis Pharmaceuticals (ZNTL) Long-Term Deferred Tax (2019 - 2021) Analysis & Trends
Zentalis Pharmaceuticals' Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $716000.0 for Q2 2021.
- On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $716000.0 in Q2 2021; TTM through Jun 2021 was $716000.0, a N/A change from a year earlier, with the FY2019 full-year figure at $841000.0, changed N/A from the prior year.
- Long-Term Deferred Tax fell to $716000.0 in Q2 2021 per ZNTL's latest filing, from $3.5 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $3.5 million in Q1 2020 and bottomed at $716000.0 in Q2 2021.
- The 3-year median for Long-Term Deferred Tax is $841000.0 (2019), against an average of $1.7 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Zentalis Pharmaceuticals | 312.67 Mn | 312.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 716,000.00 |
| Mar 31, 2020 | 3.53 Mn |
| Dec 31, 2019 | 841,000.00 |